
Opinion|Videos|July 23, 2024
Baclofen Pump for Treatment of Severe Spasticity
A panel of experts discuss how intrathecal baclofen ITB pumps have changed over time.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- How have the design, programmability, and safety features of Intrathecal baclofen pumps changed over time?
Advertisement
Related to this article

Jeffrey Cohen, MD, professor of neurology and staff physician at the Cleveland Clinic Mellen Center for Multiple Sclerosis, discusses interim BREAKFREE-2 findings for zola-cel, a CD19-directed CAR T cell therapy, in relapsing and progressive MS.

Interim phase 1b/2a data showed all patients treated with high- or low-dose BB-301 for oculopharyngeal muscular dystrophy met formal response criteria.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is the history of neurology!

Although ocular signs in LEMS are typically mild and appear late, recognizing them alongside proximal weakness and autonomic symptoms can speed diagnosis and earlier detection of an associated lung cancer.

Shaida Khan, DO, associate professor of neurology at UT Southwestern Medical Center, reflected on a recent NeurologyLive Clinical Forum on generalized myasthenia gravis and discussed how FcRn and complement inhibitors are reshaping treatment algorithms for the disease.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Benitec Reports Positive Interim Results for BB-301 in Oculopharyngeal Muscular Dsytrophy
2
Examining Trontinemab in Early Alzheimer Disease: The Phase 3 TRONTIER 1 and 2 Trials
3
Understanding Cemdisiran's Mechanism of Action in Myasthenia Gravis
4
Remibrutinib Phase 3 Results in RMS, Blood Pressure Variability Findings, and Updated Stroke Rehabilitation Guidelines
5



